AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06775860
Drug: ICP-332 Placebo Tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-332 Placebo will be administered as tablet
Trial: NCT06722820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02864784
Drug: Amorphous calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
Trial: NCT05975684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times a day for 4 weeks
Trial: NCT05614544
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 for induction of general anesthesia
Trial: NCT05614544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid
Trial: NCT05570669
Drug: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking the colonoscopy preparation drug (Clensia) in two stages of administration
Trial: NCT05006638
Drug: Lipid Emulsion, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
Trial: NCT05006638
Drug: Toxogonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a drug used as an antidote for some types of pesticides
Trial: NCT06269432
Drug: Precision Antiplatelet Therapy Trial Group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
Trial: NCT06269432
Drug: Traditional Antiplatelet Therapy Control Group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
Trial: NCT04978675
Drug: Fluorine F 18 rhPSMA-7.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05028569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT06050928
Drug: Oral EP262
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT04882202
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1g IV every 6 hours for a weight \> 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight \< 50kg (maximum of 75mg/kg per 24 hours)
Trial: NCT04684277
Drug: antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: depression recieve antidepressant treatment
Trial: NCT06781281
Drug: NabPE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2
Trial: NCT05174416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
Trial: NCT05348213
Drug: Chidamide plus R-ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Trial: NCT05174013
Drug: GSK3858279
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3858279 will be administered
Trial: NCT05174013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT04885218
Drug: SHR-1209 ;placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
Trial: NCT04885218
Drug: SHR-1209 ;placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
Trial: NCT04885218
Drug: SHR-1209 ;placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
Trial: NCT06601595
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease
Trial: NCT06601595
Drug: conventional ibd medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
Trial: NCT06593782
Drug: HSK21542
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;
Trial: NCT06219499
Drug: ONC-841
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC-841 is a humanized monoclonal antibody.
Trial: NCT05406466
Drug: Cryoablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Trial: NCT04629209
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
Trial: NCT02014428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06035016
Drug: pyrotinib combined with Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
Trial: NCT06035016
Drug: treatment of physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician's choice
Trial: NCT05586789
Drug: Ranquilon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 1 mg tablets 3 times per day for 28 days
Trial: NCT05586789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets 3 times per day for 28 days
Trial: NCT05365425
Drug: Choline fenofibrate
RxNorm normalized name: Choline Fenofibrate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: choline fenofibrate 178.8mg (135mg as fenofibric acid)
Trial: NCT05365425
Drug: Policosanol
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: policosanol 10mg
Trial: NCT05354349
Drug: PRA023 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT05354349
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05354349
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05568212
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice single-agent chemotherapy regimen
Trial: NCT04230746
Drug: Bactrim DS 800Mg-160Mg Tablet
RxNorm normalized name: Bactrim DS 800mg-160mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To study effect on urinary microbiome
Trial: NCT04230746
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To study effect on urinary microbiome
Trial: NCT03737617
Drug: Cuvitru 20 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT04717986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients meeting the inclusion criteria will be randomized to receive a placebo solution every 24 hours for 12 months
Trial: NCT06584032
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/m\^2 via IV infusion, on Day 1 every three weeks.
Trial: NCT05103046
Drug: UCT-03-008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally available kinase inhibitor
Trial: NCT06079112
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0/1.25/1.5 mg/kg, intravenous (IV) infusion every cycle until disease progression or intolerable toxicity, etc.
Trial: NCT06498076
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
Trial: NCT06592027
Drug: PRECEDEX INJ★ 2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion
Trial: NCT06592027
Drug: PRECEDEX INJ★ 2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion
Trial: NCT06185543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matches active drug in size, color and taste
Trial: NCT03986086
Drug: MPH966
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP2D tablet
Trial: NCT03986086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH966 placebo table
Trial: NCT05259189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single subcutaneous injection
Trial: NCT06249802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month intake of matching placebo
Trial: NCT06097416
Drug: Neoadjuvant Chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~The CRT regimen consists of the standard algorithms: a total of 5400-5600 cGy of radiation (4500 cGy to the pelvis, with an integrated boost to the primary tumour and involved nodes of 500 cGy followed by an option boost to the primary tumour and involved nodes) delivered in 27-28 fractions, respectively, of 180-200 cGy each over a 5-6 week period.
Trial: NCT06097416
Drug: Total Neoadjuvant Therapy
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU is a fluoropyrimidine antimetabolite considered to act primarily as an inhibitor of thymidylate synthase. 5-FU is supplied as a colourless-to-faint yellow solution in 10-mL single use vials. Each 10 mL of solution contains 500 mg 5-FU, with pH adjusted to approximately 9.2 with sodium hydroxide.~Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2- diaminocyclohexane with an oxalate ligand as a leaving group. Platinum content is 48.1% to 50.1%.~All patients received the same chemotherapy (FOLFOX) and long-course chemoradiotherapy (50.4 Gy in 28 fractions) before surgery.
Trial: NCT04790916
Drug: RO7049665
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7049665, subcutaneous injection, Q2W.
Trial: NCT05858216
Drug: Chlor-Trimeton.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Package dose of Chlor-Trimeton will be administered
Trial: NCT04900116
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group, US guided PENG block will be performed with 20 ml %0.9 NaCl solution using a 22 gauge 10 mm block needle (Control Group).
Trial: NCT00000658
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000658
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000658
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06088784
Drug: ATH-399A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered drug in capsule form.
Trial: NCT06088784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered drug in capsule form.
Trial: NCT04423861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive matching placebo BID for 7 days.
Trial: NCT05097014
Drug: CHF5993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid
Trial: NCT05097014
Drug: CHF1535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid
Trial: NCT05305404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo to be administered once at 11:00PM
Trial: NCT04290871
Drug: Nitric Oxide Gas
RxNorm normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inspired NO/N2 will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment (within 48 hours after initiation of mechanical ventilation). Weaning from NO will start after 48-h consecutive NO inhalation. The physicians will follow their own institutional weaning protocols.
Trial: NCT05119101
Drug: Dexamedotomidine added to Magnesium sulfate
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we will give dexamedotomidine and mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
Trial: NCT05957380
Drug: DA-2803-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants are administered one tablet per day for 48 weeks
Trial: NCT05957380
Drug: Placebo of DA-2803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants are administered one tablet per day for 48 weeks
Trial: NCT05957380
Drug: Placebo of DA-2803-R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants are administered one tablet per day for 48 weeks
Trial: NCT04575948
Drug: Base formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base formula is a negative control
Trial: NCT05866315
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administer remifentanil
Trial: NCT06374914
Drug: Intravesical Solution
RxNorm normalized name: Rimso-50 Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
Trial: NCT04733781
Drug: Tumescent Lidocaine and Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
Trial: NCT04575103
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment \>0.5 DDD
Trial: NCT05991401
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[Period 2\] DA-8010 5mg, Clarithromycin 500mg
Trial: NCT05710237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
Trial: NCT04663282
Drug: INS068 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Trial: NCT06392282
Drug: MV-140
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MV-140 use - sublingual spray approved for recurrent UTI prevention
Trial: NCT05064137
Drug: Tricalcium phosphate fluoride varnish, 5% F-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
Trial: NCT05248152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo capsule in the hour before surgery and two intravenous doses of saline before surgical incision.
Trial: NCT06220929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Mecobalamin tablets look and smell the same.
Trial: NCT05908825
Drug: Vitamin C with AHA Exfoliative Serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.
Trial: NCT05908825
Drug: Placebo serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
Trial: NCT05117658
Drug: HA121-28 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
Trial: NCT04704908
Drug: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
Trial: NCT05264922
Drug: Tisseel Injectable Product
RxNorm normalized name: Tisseel Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue will provide an inert, biocompatible, viscous substance able to remain within the Rotator Cuff (RC) defect rather than injecting SVF cells in saline.
Trial: NCT05969834
Drug: uHCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
Trial: NCT05969834
Drug: rHCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
Trial: NCT05605002
Drug: SSRIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
Trial: NCT06410092
Drug: FTL001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion every 2 weeks
Trial: NCT06242652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous (SC) injection.
Trial: NCT05766813
Drug: Lenrispodun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenrispodun 30 mg tablets administered orally, once daily.
Trial: NCT05766813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching tablets administered orally, once daily.
Trial: NCT06277427
Drug: PRG-1801 （CAR-T against BCMA）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
Trial: NCT04871646
Drug: CKD-314 Placebo+SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-314 placebo is administered intravenously and standard of care is also performed..
Trial: NCT04960202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet or capsule)
Trial: NCT06012552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application as in the control group
Trial: NCT05018533
Drug: TAKC-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Solution
Trial: NCT05018533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Solution
Trial: NCT06035757
Drug: Bridion 200 MG in 2 ML Injection
RxNorm normalized name: Bridion 200 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex is administered at the end of surgery after assessment of the level of neuromuscular blockade is done. The dosage of each reversal agent is determined with response to TOF or PTC.
Trial: NCT05654818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
Trial: NCT05851261
Drug: PA3670
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as control